How does a former FDA reviewer mess up a BLA? Including

New Post Public Reply Private Reply Replies (2) Message Board
onestepahead Riztheinvestor #114775
732
How does a former FDA reviewer mess up a BLA? Including changing protocols and not supplying data requested for over 18 months by the FDA?

I believe Amarex was shorts or BP ace in the hole. They somehow compromised the company/CEO Kazem Kazempour.

The NP email that was leaked by giving it to the court was done for one reason. To further tank the stock

That email was not only privileged (the blurb that it was private was included in the court documents) but HAD NO BEARING ON THE CASE!!!

It was inconsequential to the judges decision. Note that not only did Sidley attorneys not even address the email in any of their documents but neither did the judge.

Amarex attorneys also knew that email would NEVER come up again in court as it had nothing to do with whether the MSA had a clause that said Cytodyn must get their EDC and conduct an audit on request

How are those clauses affected in any relevant way by anything in NP email?

The fact is Amarex leaked it for one purpose which was to inflict more damage to Cytodyn

All this brings us to this week. I don't believe it's any coincidence that the SP is being attacked so heavily with over 60% short interest this particular week!

Guess what comes on Friday? Cytodyn must put up the $6.5 million Bond (which Cytodyn suggested as a good faith gesture until the arbitration which the judge said Cytodyn has a good chance of prevailing) as their part in the judgement. And on Monday Amarex is scheduled to begin handing over Master Trial data followed by an audit in February.

Without that Bond, I guarantee come Monday morning, Amarex attorneys will submit a motion that they don't have to hand over the data or submit to an audit as Cytodyn failed to put up the Bond

If you were Amarex or the powers that had compromised them, you would do everything in your power this week to stop that.

I predict this heavy drop in the share price will reverse by next Monday if Cytodyn makes the bond requirements this Friday.

If not, then the data isn't forthcoming, Cytodyn will appear insolvent and the end is near.

Hold the line!
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Castle Biosciences Unveils Key Data on TissueCypher at ACG

Updated Category News Views 289

New Insights from Castle Biosciences at Annual Meeting Castle Biosciences, Inc. (NASDAQ: CSTL) recently highlighted groundbreaking research at a prestigious conference, showcasing its innovative TissueCypher Barrett's Esophagus test. This test provides critical risk insights that go beyond traditional pathology, influencing clinical management for early intervention in...

Continue Reading
Ben Foster Takes Charge as Chair of Rural Broadband Board

Updated Category News Views 97

Announcement of Ben Foster's Chair Appointment In a significant development for rural connectivity, Ben Foster, President and CEO of Twin Valley, has been appointed as the chair of the National Rural Broadband Association (NTCA). As a leader of Kansas' largest independently owned broadband and communications company, Foster's new role marks an important step for improving...

Continue Reading
Interoil's Bond Payment Restructuring Proposal Explained

Updated Category News Views 260

Interoil's Bond Payment Restructuring Proposal Interoil Exploration and Production ASA (the "Company") has initiated a process with Nordic Trustee AS to gather bondholders for a written resolution. This action concerns the senior secured callable bonds identified by ISIN NO 001 0729908 (the "Bonds"). Purpose of the Written Resolution The primary goal of this resolution is...

Continue Reading
DoubleLine Income Solutions Fund Announces Upcoming Distribution

Updated Category News Views 103

DoubleLine Income Solutions Fund Declares Distribution The DoubleLine Income Solutions Fund (the "Fund"), recognized under the symbol DSL on the New York Stock Exchange, has announced a forthcoming distribution of $0.11 per share. It’s important for investors to stay informed about the timing and details of these distributions. Distribution Overview This distribution...

Continue Reading
Interoil Reports October Production Growth and Updates

Updated Category News Views 118

Key Production Metrics and Overview Interoil Exploration and Production ASA has recently released its production metrics, showcasing a notable improvement in operational output for October. The total operated production in October averaged 2,239 barrels of oil equivalent per day (boepd), representing an increase of 157 boepd from the previous month. This positive trend...

Continue Reading